Viridian Therapeutics Stock (NASDAQ:VRDN)
Previous Close
$20.24
52W Range
$11.40 - $27.20
50D Avg
$22.76
200D Avg
$17.17
Market Cap
$1.57B
Avg Vol (3M)
$1.52M
Beta
1.11
Div Yield
-
VRDN Company Profile
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| MRUS | Merus N.V. |
| BPMC | Blueprint Medicines Corporation |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| REPL | Replimune Group, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ACLX | Arcellx, Inc. |
| GPCR | Structure Therapeutics Inc. |
| ETNB | 89bio, Inc. |
| PCVX | Vaxcyte, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| KURA | Kura Oncology, Inc. |
| CYTK | Cytokinetics, Incorporated |